Results: Serum levels of PINP (47.0 ± 20.2 vs 58.1 ± 28.6 μg/L, P < .001) and OC (18.2 ± 7.5 vs 20.6 ± 9.8 μg/L, P < .001) were decreased in women with PCOS compared with controls, whereas no significant differences were found in CTX and 25OHD levels. Age-stratified analyses suggested that PINP (50.5 ± 21.7 vs 68.2 ± 26.6 μg/L, P < .001) and OC levels (20.4 ± 7.6 vs 25.5 ± 9.6 μg/L, P < .001) were decreased only in the younger age group (≤30 years) women with PCOS compared with controls. The formation markers and resorption marker decreased with age in both study groups.
| INTRODUCTION
Polycystic ovary syndrome (PCOS) constitutes the most common endocrine disorder in women of reproductive age, with a prevalence ranging between 6% and 15%, depending on the criteria used for the diagnosis.
1 Women with PCOS often suffer from oligo/amenorrhoea, hyperandrogenism, obesity and hyperinsulinaemia all known characteristics that may have long-term effects on bone mineral density (BMD).
While oestrogen plays a major role in the development and maintenance of bone mass in women, the influence of androgens in women has not been fully elucidated. Aromatization of androgens to oestrogens in the ovary and extra-glandular tissue, with subsequent binding to oestrogen receptors in target tissues, is thought to be the primary mechanism of androgen action on bone metabolism. 2 Thus, the ovarian-and adrenal-derived hyperandrogenism in women with PCOS could affect bone turnover and BMD. On the other hand, peak bone mass is achieved from late adolescence to the early thirties, and menstrual dysfunction during this critical period may possibly influence the same. 3 Whether the menstrual irregularities and amenorrhoea in younger women with PCOS could possibly predispose them to osteoporosis in later life remains elusive. To date, however, data regarding BMD in women with PCOS are conflicting; no difference in BMD, increased and decreased BMD have been observed, [4] [5] [6] [7] [8] [9] and therefore, it is not known whether BMD is altered in PCOS.
The dual energy X-ray absorptiometry (DXA) and peripheral quantitative computed tomography (pQCT), which have been used to evaluate BMD in women with PCOS do not provide assessment of dynamic bone remodelling, which can be measured via biochemical bone turnover markers (BTMs). BTMs provide noninvasive assessment of bone turnover and skeletal pathology and are sensitive enough in the assessment of acute changes in bone turnover, providing a more representative view of overall bone loss than that obtained by measuring BMD at specific skeletal sites.
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Type I collagen which constitutes 90% of the bone matrix is synthesized as a precursor procollagen, cleavage of which releases peptides including procollagen type I amino-terminal propeptide (PINP)
into the circulation, and concentrations of PINP reflect the rate of collagen synthesis, and thus bone formation. 12 The carboxy-terminal cross-linking telopeptide of type I collagen (CTX) is released from the bone matrix during bone resorption and reflects the degradation of type I collagen, and thus bone resorption. Osteocalcin (OC) is the most abundant noncollagenous protein in the bone matrix. The proportion of OC that is not incorporated into bone is instead released into the circulation, where the levels correlate with the bone formation rate. The purpose of this study was to evaluate biochemical markers of bone turnover and 25OHD and their associations with metabolic parameters and to assess the age-related changes of BTMs in women with PCOS.
| MATERIALS AND METHODS

| Subjects
The study population consisted of 298 women with PCOS and 194 healthy women who participated in six Nordic PCOS studies performed in two countries: four studies in Finland and two in Sweden. [13] [14] [15] [16] [17] [18] PCOS was diagnosed according to the Rotterdam criteria. 19 Biochemical hyperandrogenism was defined as serum testosterone (T) ≥2.3 nmol/L and clinical hyperandrogenism as a Ferriman-Gallwey hirsutism score of >7. The reference population consisted of women with regular menstrual cycles, without hirsutism or hyperandrogenism, and normal ovaries as assessed by ultrasonography. Women using medication known to affect bone metabolism and steroid synthesis were excluded from the study.
Moreover, a washout period of at least 2 months was required for women using hormonal contraception prior to participation in the study. Blood samples were collected in a fasting state at each study centre, and 65% of the serum samples were stored at −80°C and 35% at −20°C for further analyses. Informed written consent was obtained from all subjects at the original study sites, and the study was approved by the Ethics Committee of Oulu University Hospital.
| Methods
Serum concentrations of PINP, CTX, OC and 25OHD were deter- 
| Statistical analysis
Statistical analysis was performed using spss 22.0 software (IBM SPSS Statistics for Windows, version 22.0, IBM Corp., Armonk, NY). To evaluate the changes in BTM levels with regard to age, the subjects were divided into three groups: ≤30 years, 31-40 years and 41 years to menopause. Univariate analysis of variance (ANOVA) was used to control for the effects of age and body mass index (BMI) in the whole study population. Furthermore, the effect of BMI in individual age groups was also controlled by univariate ANOVA. Overall comparisons of continuous variables between age groups were carried out using one-way ANOVA. Spearman's correlation coefficient was used to assess correlation between different variables, and adjustment for BMI was carried out by way of partial correlation analyses. The limit of statistical significance was set at P < .05.
| RESULTS
| Baseline characteristics
Women with PCOS had higher BMI (27.1 ± 6.0 vs 24.9 ± 5.1) compared with controls (Table 1) . Furthermore, levels of T, FAI and A were significantly higher and those of SHBG lower in the PCOS group compared with the controls after adjusting for age and BMI. When the subjects were divided into different age groups, levels of T, FAI and A were significantly higher in women with PCOS aged ≤30 years and 31-40 years. In women of 41 years to menopause, SHBG levels were lower and the FAI was higher in the PCOS group compared with controls.
| Biochemical markers of bone turnover and 25OHD
The concentrations of PINP and OC were significantly decreased, even after adjusting for age and BMI, in the PCOS group compared with controls in the whole study population, whereas the levels of CTX and 25OHD did not differ in any of the age groups (Table 2) .
Interestingly, 40% of the women with PCOS and 29% of the controls were found to be 25OHD-deficient (25OHD <20 μg/L), and 42% of women with PCOS and 53% of control women had insufficient levels of 25OHD (25OHD between 20-29 μg/L). 
| Changes with age
Age-stratified analysis showed that serum concentrations of PINP, OC and CTX decreased with age until menopause in both groups while serum levels of 25OHD remained unchanged ( Figure 1 , Table 2 ).
| Correlation analyses
Serum concentrations of PINP, OC and CTX were positively correlated with each other in both study groups (r s = .655-0.876, P < .001), but not with 25OHD levels (data not shown). These correlations remained significant after adjustment for BMI. Levels of PINP, OC and CTX correlated negatively with age (P < .001) and Data shown as mean ± standard deviation/estimated marginal means ± standard error. P values adjusted for age and BMI in all age groups and adjusted for BMI in individual age groups. a n = 93. b n = 60. c n = 241. ***P < .001 **P < .01 *P < .05.
BMI (P < .001) in both study groups (Table 3 
| DISCUSSION
The results demonstrated that serum levels of the bone formation markers PINP and OC were decreased in women with PCOS compared PCOS, the findings in the control population were consistent with the results of earlier studies. 22, 23 The relationships between hormones and bone turnover markers may differ before and after peak bone mass, which may explain some of the observed differences between young and older women. 24 Given that serum T levels and the FAI are commonly increased in women with PCOS, we wanted to explore how this affects bone turnover. There were only weak positive correlations between the levels of BTMs and T and SHBG in the whole PCOS group. In women with PCOS aged ≤30 years, levels of BTMs were not correlated with those of T, but weak positive correlations between BTMs and SHBG, and weak negative correlations between BTMs and DHEAS were observed, as found earlier in healthy young women. 24 After adjustment for BMI, these correlations remained insignificant suggesting that androgens may not be associated with decreased bone formation in our subjects.
We found no significant differences in the concentrations of 25OHD between women with PCOS and controls, as reported earlier. 25 The majority of our study population, especially obese women with PCOS, were found to be 25OHD-deficient. This is in accordance with the results of studies showing that vitamin D deficiency is common in women with PCOS, and obese women with the condition have lower levels of 25OHD than their lean counterparts. 26 However, it must be noted that the seasonal variation of 25OHD was not taken into account in the present study. Furthermore, there were no significant correlations between PINP, OC, CTX and 25OHD in either of the study groups or when the subjects were analysed in different age groups and the results did not change after adjusting for 25OHD levels. This suggests that 25OHD may not have a major influence on bone turnover and supports observations of earlier studies indicating that 25OHD is unlikely to influence the concentrations of PINP, OC or CTX. 27, 28 Thus, differences in the levels of BTMs between controls and women with PCOS cannot be explained by 25OHD levels.
The study population included women with PCOS from a young to a premenopausal age, which allowed relatively detailed evaluation of age-related changes in bone turnover. Although the subjects were recruited at different study sites, Rotterdam criteria were used for the diagnosis of PCOS. All blood samples were obtained in a fasting state, which is particularly important as regards CTX levels, as they decrease after food intake. 12 There is no significant seasonal variation in BTM levels 29 and thus factors leading to biological variability were minimized.
The present study has some limitations. T A B L E 3 Spearman's correlation coefficient between various parameters in the study population when the samples taken in follicular phase were analysed separately.
Furthermore, earlier studies have shown that changes in BTMs over the menstrual cycle are so small that the effect of the menstrual cycle can be considered to be insignificant. [10] [11] [12] The washout period from hormonal contraceptives was 2 months, which might have influenced the levels of BTMs, but earlier studies have shown that the effect of oral contraception on BTMs, particularly in young women, is insignificant. 12, 30 Another limitation might be the use of stored samples.
However, earlier studies have shown that serum BTM samples are stable for at least 12 months to 3 years when stored at −80°C, 31, 32 and most of the samples in the present study were kept at this temperature.
In conclusion, we found that younger women with PCOS have decreased circulating PINP and OC levels and unchanged CTX concentrations compared with age-matched controls. These observations suggest that bone formation in these women may be decreased and result in lower bone mass in the long run, as earlier studies have suggested that BTMs may reflect underlying changes in bone mass or bone histomorphometric parameters. 33 However, the clinical relevance as well as the correlation with bone density measurements should be further investigated in future studies.
